Ignite Creation Date:
2024-05-06 @ 6:14 PM
Last Modification Date:
2024-10-26 @ 2:44 PM
Study NCT ID:
NCT05593419
Status:
RECRUITING
Last Update Posted:
2022-10-25
First Post:
2022-10-21
Brief Title:
Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers
Sponsor:
Peking University
Organization:
Peking University
Study Overview
Official Title:
Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers
Status:
RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We have established a machine learning model based on effective TIIC signature which could select GC patients who may benefit from immunotherapy
The current study aims to enroll 300 GC patients as a validation cohort to vertify the accuracy of TIIC signature in predicting immunotherapy efficacy
The current study aims to enroll 300 GC patients as a validation cohort to vertify the accuracy of TIIC signature in predicting immunotherapy efficacy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None